HDAC6 and androgen insensitivity syndrome: Additional experiments which (i) more closely simulate the clinical scenario, (ii) investigate the longer-term impacts of HDAC6 inhibition on AIS outcomes and (iii) utilise unbiased screening approaches to elucidate the mechanisms by which HDAC6 inhibition protects against AIS-induced damage are needed to progress this promising avenue.